[BIOINFO 2024]

Drug Discovery with Multi-Task Learning Platform

Jisun Jung

AICloud

**Corresponding author: jjs_5655@aicloud.biz*

Drug candidate's absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics are crucial factors in predicting their potential success in drug development. Recently, AI-driven technologies for predicting ADMET properties have gained significant attention, serving as essential tools in the early stages of drug discovery and development. ADMET-AI is a platform designed to meet this demand, allowing for the rapid analysis and prediction of ADMET characteristics from large compound datasets. ADMET-AI utilizes the Chemprop-RDKit model based on a Graph Neural Network (GNN). Chemprop represents molecular structures as graphs, where atoms and bonds are depicted as nodes and edges, respectively. This model integrates over 200 physicochemical features computed by RDKit, enhancing the predictive performance by capturing intricate molecular interactions. Chemprop-RDKit's architecture enables efficient and scalable ADMET predictions across drug candidates. The platform was trained using 41 ADMET datasets from the Therapeutics Data Commons (TDC), which include both regression and classification tasks. This multi-task learning approach allows ADMET-AI to simultaneously predict multiple ADMET properties with high accuracy. Its efficient data handling makes it suitable for large compound datasets, processing millions of compounds in a fraction of the time required by other models. ADMET-AI is a powerful tool for researchers, helping streamline the analysis of drug candidates during development. Its capability for rapid, large-scale analysis is expected to play a critical role in drug design and development, contributing to the increased likelihood of success in new drug discoveries.